1. Home
  2. MLKN vs PHAT Comparison

MLKN vs PHAT Comparison

Compare MLKN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MillerKnoll Inc.

MLKN

MillerKnoll Inc.

HOLD

Current Price

$17.35

Market Cap

1.0B

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$11.70

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLKN
PHAT
Founded
1905
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
894.0M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
MLKN
PHAT
Price
$17.35
$11.70
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$19.83
AVG Volume (30 Days)
1.1M
1.0M
Earning Date
03-25-2026
04-30-2026
Dividend Yield
4.31%
N/A
EPS Growth
N/A
42.72
EPS
0.98
N/A
Revenue
$3,669,900,000.00
$175,110,000.00
Revenue This Year
$5.94
$93.04
Revenue Next Year
$3.78
$58.91
P/E Ratio
$17.77
N/A
Revenue Growth
1.14
216.93
52 Week Low
$13.77
$2.21
52 Week High
$23.18
$18.31

Technical Indicators

Market Signals
Indicator
MLKN
PHAT
Relative Strength Index (RSI) 55.61 46.67
Support Level $16.55 $11.04
Resistance Level $17.77 $12.25
Average True Range (ATR) 0.60 0.69
MACD 0.45 0.07
Stochastic Oscillator 81.70 31.76

Price Performance

Historical Comparison
MLKN
PHAT

About MLKN MillerKnoll Inc.

MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: